- Home
- OPRT vs GNLX Comparison
OPRT vs GNLX Comparison
Compare OPRT & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRT
- GNLX
- Stock Information
- Founded
- OPRT 2005
- GNLX 2001
- Country
- OPRT United States
- GNLX United States
- Employees
- OPRT N/A
- GNLX N/A
- Industry
- OPRT Finance: Consumer Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- OPRT Finance
- GNLX Health Care
- Exchange
- OPRT Nasdaq
- GNLX Nasdaq
- Market Cap
- OPRT 221.5M
- GNLX 184.4M
- IPO Year
- OPRT 2019
- GNLX 2023
- Fundamental
- Price
- OPRT $4.61
- GNLX $2.63
- Analyst Decision
- OPRT Buy
- GNLX Strong Buy
- Analyst Count
- OPRT 3
- GNLX 4
- Target Price
- OPRT $6.50
- GNLX $18.25
- AVG Volume (30 Days)
- OPRT 473.6K
- GNLX 233.3K
- Earning Date
- OPRT 05-08-2025
- GNLX 05-08-2025
- Dividend Yield
- OPRT N/A
- GNLX N/A
- EPS Growth
- OPRT N/A
- GNLX N/A
- EPS
- OPRT N/A
- GNLX N/A
- Revenue
- OPRT $763,617,000.00
- GNLX $8,000.00
- Revenue This Year
- OPRT $28.45
- GNLX N/A
- Revenue Next Year
- OPRT $9.19
- GNLX N/A
- P/E Ratio
- OPRT N/A
- GNLX N/A
- Revenue Growth
- OPRT N/A
- GNLX N/A
- 52 Week Low
- OPRT $2.05
- GNLX $1.60
- 52 Week High
- OPRT $9.25
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- OPRT 42.98
- GNLX 42.31
- Support Level
- OPRT $4.05
- GNLX $2.30
- Resistance Level
- OPRT $5.28
- GNLX $2.68
- Average True Range (ATR)
- OPRT 0.48
- GNLX 0.26
- MACD
- OPRT -0.04
- GNLX 0.05
- Stochastic Oscillator
- OPRT 31.25
- GNLX 55.49
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.